

DRUG QUANTITY MANAGEMENT POLICY - PER DAYS

POLICY: semaglutide injection (Wegovy – Novo Nordisk Inc.) Duration Limit

DATE REVIEWED: 06/16/2021

OVERVIEW

Wegovy is a glucagon-like peptide-1 (GLP-1) receptor agonist indicated as an adjunct to a reduced calorie diet and increased physical activity for chronic weight management in adult patients with an initial body mass index (BMI) of 30 kg/m² or greater (obesity) or 27 kg/m² or greater (overweight) in the presence of at least one weight-related comorbid condition (e.g., hypertension, type 2 diabetes mellitus, or dyslipidemia).¹

Dosing

Initiate Wegovy with a dose of 0.25 mg injected subcutaneously once weekly and follow the dose escalation schedule in the table below.

Dose Escalation Schedule

Weeks	Weekly Dose	
1 through 4	0.25 mg	Dose escalation
5 through 8	0.5 mg	
9 through 12	1 mg	
13 through 16	1.7 mg	
Week 17 and onward	2.4 mg	Maintenance dose

If patients do not tolerate a dose during dose escalation, consider delaying dose escalation for 4 weeks. If more than two consecutive doses are missed, resume dosing as scheduled or, if needed, reinitiate Wegovy and follow the dose escalation schedule, which may reduce the occurrence of gastrointestinal symptoms associated with re-initiation of treatment. If patients do not tolerate the maintenance 2.4 mg once weekly dose, the dose can be temporarily decreased to 1.7 mg once weekly, for a maximum of 4 weeks. After 4 weeks, increase Wegovy to the maintenance 2.4 mg once weekly. Discontinue Wegovy if the patient cannot tolerate the 2.4 mg dose.

Wegovy 0.25 mg/0.5ml prefilled pen-injector	Maximum quantity per 365 days = 4 prefilled injectors
Wegovy 0.5 mg/0.5ml prefilled pen-injector	Maximum quantity per 365 days = 4 prefilled injectors
Wegovy 1 mg/0.5ml prefilled pen-injector	Maximum quantity per 365 days = 4 prefilled injectors
Wegovy 1.7 mg/0.75ml prefilled pen-injector	Maximum quantity per 365 days = 4 prefilled injectors
Wegovy 2.4 mg/0.75ml prefilled pen-injector	Maximum quantity per 28 days = 4 prefilled injectors

Wegovy is supplied in prefilled, disposable, single-dose pen-injectors. A quantity of four 0.25 mg, 0.5 mg, 1 mg, and 1.7 mg prefilled pen-injectors will be covered per 365 days. This is enough drug for dose escalation to the maintenance dose. A quantity of four 2.4 mg prefilled pen-injectors will be covered per 28 days. This is enough drug to allow for once weekly maintenance dosing. The objective of this program is to manage potential dose escalation and to provide a sufficient quantity for indications covered by the *Express Scripts Weight Loss – Glucagon-Like Peptide-1 Agonists Prior Authorization Policy*.² One-time exceptions for missed doses, re-initiation of treatment, or temporary dose reduction are provided through coverage review.

CRITERIA

Wegovy 0.25 mg/0.5ml,

1. For patients who do not tolerate the 0.25 mg dose during dose escalation and an additional 4 weeks (total of 8 weeks) of the 0.25 mg doses is needed, a one-time approval of four syringes may be approved.
2. If more than two consecutive 0.25 mg doses are missed, and re-initiation of treatment is needed, a one-time approval of four syringes may be approved.

Wegovy 0.5 mg/0.5 ml

1. For patients who do not tolerate the 0.5 mg dose during dose escalation and an additional 4 weeks (total of 8 weeks) of the 0.5 mg doses is needed, a one-time approval of four syringes may be approved.
2. If more than two consecutive 0.5 mg doses are missed, and re-initiation of treatment is needed, a one-time approval of four syringes may be approved.

Wegovy 1 mg/0.5 ml

1. For patients who do not tolerate the 1 mg dose during dose escalation and an additional 4 weeks (total of 8 weeks) of the 1 mg doses is needed, a one-time approval of four syringes may be approved.
2. If more than two consecutive 1 mg doses are missed, and re-initiation of treatment is needed, a one-time approval of four syringes may be approved.

Wegovy 1.7 mg/0.75 ml

1. For patients who do not tolerate the 1.7 mg dose during dose escalation and an additional 4 weeks (total of 8 weeks) of the 1.7 mg doses is needed, a one-time approval of four syringes may be approved.
2. If more than two consecutive 1.7 mg doses are missed, and re-initiation of treatment is needed, a one-time approval of four syringes may be approved.
3. If patients do not tolerate the maintenance 2.4 mg once weekly dose and the dose needs to be temporarily decreased to 1.7 mg weekly, a one-time approval of four syringes may be approved. ***Note: After the four additional weeks of 1.7 mg, the dose should be increased to 2.4 mg. If the patient still cannot tolerate the 2.4 mg dose after the temporary dose reduction to 1.7 mg, Wegovy should be discontinued.***

Wegovy 2.4 mg/0.75 ml

No quantity overrides are recommended.

REFERENCES

1. Wegovy [prescribing information]. Plainsboro, NJ: Novo Nordisk Inc., June 2021.
2. Weight Loss – Glucagon-Like Peptide-1 Agonists prior authorization policy. Express Scripts, Inc. Reviewed 06/xx/2021.

HISTORY

Type of Revision	Summary of Changes	Date
New policy	Reviewed and approved by TAC	06/16/2021